Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 5/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9795959 | 0.80 | GAA (0.71) | GAAKMT2ASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL20583292 | 0.80 | GAA (0.71) | GAAKMT2ASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL9795955 | 0.80 | GAA (0.71) | GAAKMT2ASMN1; SMN2RAB9ANPC1 | |
| Hydrochloric Acid SCHEMBL9674660 | 0.79 | GAA (0.66) | GAAKMT2ASMN1; SMN2RAB9ANPC1 | |
| Hydrochloric Acid SCHEMBL9674665 | 0.79 | GAA (0.66) | GAAKMT2ASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL23515734 | 0.79 | GAA (0.69) | GAAKMT2ASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL27178272 | 0.77 | GAA (0.86) | GAAKMT2ARAB9ANPC1MEN1 | |
| SCHEMBL27178276 | 0.77 | GAA (0.86) | GAAKMT2ARAB9ANPC1MEN1 | |
| SCHEMBL9674721 | 0.74 | KMT2A (0.55) | GAAKMT2ASMN1; SMN2RAB9ANPC1 | |
| Hydrochloric Acid SCHEMBL9675169 | 0.74 | KMT2A (0.55) | GAAKMT2ASMN1; SMN2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969339-B2 | Compositions and methods for bone formation and modeling | ENZO BIOCHEM, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969339-B2 | Compositions and methods for bone formation and modeling | ENZO BIOCHEM, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20130172332-A1 | COMPOSITIONS AND METHODS FOR BONE FORMATION AND MODELING | ENZO BIOCHEM, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130172332-A1 | COMPOSITIONS AND METHODS FOR BONE FORMATION AND MODELING | ENZO BIOCHEM, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-8367822-B2 | Compositions and methods for bone formation and remodeling | ENZO THERAPEUTICS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367822-B2 | Compositions and methods for bone formation and remodeling | ENZO THERAPEUTICS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172332-A1 | COMPOSITIONS AND METHODS FOR BONE FORMATION AND MODELING | LRP6, BMP6, WNT3A | GAA 3072/4885KMT2A 4661/4885SMN1; SMN2 4089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.